HedgePath Pharmaceuticals' Pathway for Filing SUBA BCCNS NDA Clarified in Meeting with FDA

Author's Avatar
Oct 09, 2018
Article's Main Image

Key components of SUBA BCCNS NDA agreed to in FDA meeting minutes

Expanded efficacy and safety modules required, which is anticipated to push proposed NDA submission into Q1 2019

PR Newswire